Bank of America
AQST icon

Bank of America’s Aquestive Therapeutics AQST Stock Holding History

Bank of America’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.94M Sell
1,668,423
-736,627
-31% -$3.1M ﹤0.01% 3306
2026
Q1 		$9.98M Buy
2,405,050
+1,197,459
+99% +$4.86M ﹤0.01% 2962
2025
Q4 		$7.8M Sell
1,207,591
-14,544
-1% -$90.6K ﹤0.01% 3032
2025
Q3 		$6.83M Sell
1,222,135
-61,005
-5% -$264K ﹤0.01% 3704
2025
Q2 		$4.25M Sell
1,283,140
-47,385
-4% -$136K ﹤0.01% 4067
2025
Q1 		$3.86M Buy
1,330,525
+640,241
+93% +$1.94M ﹤0.01% 4078
2024
Q4 		$2.46M Buy
690,284
+621,614
+905% +$2.87M ﹤0.01% 4264
2024
Q3 		$342K Sell
68,670
-161,484
-70% -$628K ﹤0.01% 5724
2024
Q2 		$598K Buy
230,154
+207,561
+919% +$693K ﹤0.01% 5234
2024
Q1 		$96.2K Buy
22,593
+13,881
+159% +$46.2K ﹤0.01% 6260
2023
Q4 		$17.6K Buy
+8,712
New +$15.4K ﹤0.01% 6809
2023
Q1 		– Sell
-102
Closed -$92 – 7783
2022
Q4 		$92 Sell
102
-482
-83% -$453 ﹤0.01% 7684
2022
Q3 		$0 Sell
584
-128
-18% -$145 ﹤0.01% 7807
2022
Q2 		$0 Sell
712
-3,870
-84% -$5.15K ﹤0.01% 7989
2022
Q1 		$12K Sell
4,582
-31,789
-87% -$92.8K ﹤0.01% 7678
2021
Q4 		$141K Buy
36,371
+28,814
+381% +$145K ﹤0.01% 6696
2021
Q3 		$33K Sell
7,557
-21,171
-74% -$83K ﹤0.01% 7219
2021
Q2 		$114K Sell
28,728
-9,151
-24% -$36.5K ﹤0.01% 6442
2021
Q1 		$197K Buy
37,879
+15,534
+70% +$82.6K ﹤0.01% 6050
2020
Q4 		$119K Sell
22,345
-18,406
-45% -$110K ﹤0.01% 5893
2020
Q3 		$198K Sell
40,751
-9,799
-19% -$64K ﹤0.01% 5304
2020
Q2 		$245K Buy
50,550
+24,644
+95% +$113K ﹤0.01% 5099
2020
Q1 		$57K Sell
25,906
-337
-1% -$1.28K ﹤0.01% 5812
2019
Q4 		$153K Buy
+26,243
New +$137K ﹤0.01% 5782
2019
Q3 		– Sell
-13,307
Closed -$56K – 7239
2019
Q2 		$56K Buy
13,307
+8,934
+204% +$45.7K ﹤0.01% 6259
2019
Q1 		$30K Sell
4,373
-3,660
-46% -$25.6K ﹤0.01% 6379
2018
Q4 		$50K Buy
8,033
+7,541
+1,533% +$95.2K ﹤0.01% 6214
2018
Q3 		$9K Buy
+492
New +$8.11K ﹤0.01% 6694

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Bank of America's AQST Position: Q2 2026 in Review

Bank of America reduced its Aquestive Therapeutics (AQST) stake by 31% in Q2 2026, selling an estimated $3.1M and leaving 1,668,423 shares worth $6.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3306.

Bank of America first reported a position in AQST in Q3 2018 and has held it in 28 quarters since. The position peaked at $9.98M in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Bank of America held 1,668,423 shares of Aquestive Therapeutics worth $6.94M as of Q2 2026.
  • Bank of America sold 736,627 Aquestive Therapeutics shares in Q2 2026, an estimated $3.1M.
  • Aquestive Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #3306 holding.
  • Bank of America first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • Bank of America's Aquestive Therapeutics position peaked at $9.98M in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.